LivaNova PLC
NASDAQ:LIVN
LivaNova PLC
Cash Equivalents
LivaNova PLC
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LivaNova PLC
NASDAQ:LIVN
|
Cash Equivalents
$309.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
44%
|
CAGR 10-Years
12%
|
|
Smith & Nephew PLC
LSE:SN
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
LumiraDx Ltd
NASDAQ:LMDX
|
Cash Equivalents
$100m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash Equivalents
£7.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
Angle PLC
LSE:AGL
|
Cash Equivalents
£22.2m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash Equivalents
£13.1m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LivaNova PLC's Cash Equivalents?
Cash Equivalents
309.2m
USD
Based on the financial report for Mar 31, 2024, LivaNova PLC's Cash Equivalents amounts to 309.2m USD.
What is LivaNova PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
12%
Over the last year, the Cash Equivalents growth was 44%. The average annual Cash Equivalents growth rates for LivaNova PLC have been 7% over the past three years , 44% over the past five years , and 12% over the past ten years .